Medmeme Delta, a measurement system for scientific data

pharmafield logo - pharma news

 

The global medical science measurement company Medmeme has launched a platform with a unique suite of solutions to help Medical Affairs teams harness the power of published scientific data, from basic research through to post-marketing.

These solutions, which fall under the new name Medmeme Delta, transform complex and often chaotic sets of global data from tens of thousands of different sources into current, credible and actionable intelligence. Medical Affairs teams can then align across geography and function, reduce duplicative data spend and most importantly measure the results of their scientific dissemination efforts. 

Powered by Medmeme’s Dynamic Impact Factor algorithms, these measurements offer Medical Affairs departments the only objective solution to validate their decisions and measure the results. That’s because Dynamic Impact Factor is based on companies’ imperatives, enabling Medical Affairs teams to identify the best publications and scientific experts to work with and, for the first time, assess the impact of scientific conferences.  

For example, Medmeme Delta helps pharma to review the competitive landscape within a specific therapeutic area at the touch of a button and not only measure both its own and its competitors’ reach in disseminating scientific information on a drug, but understand the impact of any particular journal publication, presenter, author, conference or even a specific presentation.

Medmeme Delta was launched at the Medical Affairs Professional Society’s Annual Meeting and is enabled through access to the world’s most comprehensive, continuously updated and integrated online repository of disseminated medical & scientific information including monitoring over 14,000 global medical conferences a year.

Simon Mason, Chief Commercial Officer, Medmeme, said: “As pharma moves from simple chemicals to more complex biologics, Medical Affairs departments have an increasingly important role to play in communicating these developments to the medical world.”